Abstract：Objective: To study the application value of Rho kinase inhibitor in the treatment of acute left heart failure (ALHF).Methods: Retrospective analysis was performed on 62 ALHF patients admitted from January 2019 to January 2020. The subjects were divided into control group and study group by referring to the random number table method, with 31 patients in each group. Both groups were given conventional treatment. The control group was treated with furtimox and spironolactone based on conventional treatment, while the study group was treated with furtimox, spironolactone and Rho kinase inhibitor (Fasudil hydrochloride) based on conventional treatment. Cardiac function index, myocardial enzyme spectrum index, total effective rate and adverse reaction rate were compared between the two groups before and after treatment. Results: Before treatment, there was no difference between the two groups in left ventricular end-systolic volum (LVSDV), left ventricular end-diastolic volume (LVEDV), left ventricular ejection fraction (LVEF), Creatine Kinase Isoenzyme-MB (CK-MB), lactate dehydrogenase, LDH and Aspartate aminotransferase (AST) levels (P>0.05).LVEF after treatment was higher, and LVSDV, LVEDV, CK-MB, LDH and AST levels were lower than those before treatment in both groups (P<0.05).After treatment, LVEF and total effective rate in the study group were higher than those in the control group, and LVSDV, LVEDV, CK-MB, LDH and AST levels were lower (P<0.05). The difference values between the two groups before and after treatment were compared, and the differences were statistically significant (P<0.05).There was no difference in the incidence of adverse reactions after treatment between the two groups (P>0.05). Conclusion: The application of Rho kinase inhibitor in ALHF treatment has a significant effect, can effectively improve the level of myocardial enzyme spectrum, and can promote the recovery of cardiac function, with fewer adverse reactions.
2021, Vol. 27 
冀公网安备13080202000677号